EXICOM · Q1 FY27 · THE VERDICT

Revenue Surge Masks Widening Loss: Exicom's Profitability Reckoning

Exicom reported 61% revenue growth to ₹331 Cr, but consolidated PAT worsened to -₹73.6 Cr, a 35.5% QoQ deterioration. The disconnect reveals the cost of growth: Hyderabad capex drag and Tritium's investment phase are masking an otherwise healthy standalone business—and testing management's Q2–Q3 breakeven claim.

Q1 FY27 results EXICOMExicom Tele-Systems Ltd17 Aug 2026 · 6 min read

Consolidated Revenue

₹331.1 Cr

+61.2% YoY

Consolidated PAT

-₹73.6 Cr

-35.5% QoQ (worsened)

Stand-alone PAT

₹4.9 Cr

2.1% margin, profitable

Order Book

₹1,400 Cr

60+ months visibility

The core paradox

Revenue surged 61% to ₹331.1 Cr, yet consolidated net profit worsened to -₹73.6 Cr, deteriorating 35.5% quarter-on-quarter. This is the defining tension of Exicom's quarter. The company delivered strong order execution and revenue growth, but profitability moved backward. Why? Because Hyderabad capex is dominating the P&L: depreciation jumped 67% YoY (a ₹10.3 Cr increase to ₹12 Cr), and the plant is running parallel with Gurgaum during transition, adding ₹8.7 Cr in fixed costs. Tritium, the acquired EV charging business, continues to run at a loss. Standalone—the core Critical Power and wallbox charger business—is profitable and growing; consolidated is a turnaround in progress.

Breaking down the pieces

Standalone delivered ₹188 Cr in revenue (73% YoY growth) and ₹4.9 Cr in PAT at a 2.1% margin. Critical Power (₹177 Cr, +80% YoY) is firing: a large Indian telco order (₹85 Cr), BharatNet wins (₹700+ Cr pipeline), and tower company battery deals drove the surge. EBITDA margin improved to 8.8%, up 137% YoY on operating leverage. Tritium (the consolidated adder) reported USD 10.5M in revenue (₹87 Cr equivalent) with USD 20.8M in bookings—doubled YoY—but remains loss-making. Trials with Fortune 100 companies are mid-to-advanced stage; the upside is real, but conversion is unproven. The math: standalone profitability is genuine; Tritium and Hyderabad depreciation together pull consolidated into a -₹73.6 Cr loss.

Management's key claims vs. what the data shows

Revenue grew 61% YoY to ₹331 Cr

Delivered ₹331.1 Cr, 61.2% growth. Order execution strong.

Supported

Consolidated EBITDA loss narrowed to ₹22.5 Cr

Actual ₹21.9 Cr loss. Improved from ₹38.6 Cr YoY, but worsened QoQ despite 61% growth.

Supported but misleading (cherry-picks YoY)

Stand-alone PAT ₹4.9 Cr at 2.1% margin (turnaround)

Delivered ₹4.9 Cr, 2.1% margin. Standalone is profitable.

Supported

Tritium bookings doubled to USD 20M

Actual USD 20.8M. Momentum is real; conversion timing unproven.

Supported

EBITDA/PAT breakeven next 2 quarters (Q2–Q3 FY27)

Guidance stated but not quantified. Hyderabad parallel costs expected to phase out, but timeline not specified.

Unverified

Critical Power order book ₹1,000+ Cr; exports scaling 8%→15%

Order book ₹1,400 Cr confirmed. Q1 exports only ₹15 Cr (8% of segment). Target is aspirational.

Overstated (on exports)

What changed on this call

Hyderabad capex impact quantified in full: ₹8.7 Cr parallel run costs + ₹10.3 Cr depreciation jump (67% YoY). Prior call less explicit.
Tritium bookings accelerated: USD 20.8M (doubled from prior call). New product trials TRI-FLEX, DC-FLEX, GRID-FLEX advancing.
Order book formalized at ₹1,400 Cr consolidated (60+ months visibility). Prior call alluded to large wins; now quantified.
Breakeven timeline narrowed to Q2–Q3 FY27 (vs. prior 'over next 2 quarters'). More specific but still a range.

Bull-bear ledger

What an investor should weigh

₹1,400 Cr order book provides 60+ months structural revenue visibility
Standalone profitability + 80% revenue growth in Critical Power signal genuine operating leverage
Tritium bookings momentum accelerating; Fortune 100 trials advancing (TRI-FLEX, DC-FLEX, GRID-FLEX)
Market leadership: >50% wallbox charger share; 100% share for international 7-brand chargers
Secular tailwinds: 5G rollout (BharatNet ₹700+ Cr), EV adoption surge (31K car registrations Q1, highest ever)
Consolidated PAT -₹73.6 Cr; absolute loss remains substantial despite 61% revenue growth
QoQ profitability deterioration -35.5% despite +61% growth is a red flag for margin pressure
Hyderabad capex drag (₹8.7 Cr parallel run, ₹10.3 Cr depreciation) timeline to phase-out vague
Tritium turnaround unproven: trials mid-to-advanced stage, Fortune 100 contracts not yet signed
Breakeven guidance vague: 'Q2 or Q3' with no quantified EBITDA bridge
Working capital intensity: 57% revenue growth lifts receivables/inventory; cash cycle extended
Management tone: confident but vague on specifics (capacity numbers initially inconsistent)

How the market is reading this

The stock fell 6.05% on day 1 post-result but recovered partially, trading -1.26% by day 3. The mixed reaction—initial sell-off followed by incomplete recovery—suggests the market found the print cautious but not capitulation-level. Valuation context: at ₹151.79 (as of Aug 14), the stock trades 17% below its all-time high of ₹182.9, below both its SMA20 (₹160.11) and SMA50 (₹160.96). RSI sits at 38.6 (neutral, not oversold). Volume is normal—no panic selling. Ownership flows: FII holdings are flat at 0.20%, DII trimmed 3.15pp to 0.31%, and promoter stakes fell 1.27pp to 65.20%. No insider enthusiasm, but no panic exits either. Bulk deals in June (₹166–₹172 range) were trading activity; no obvious insider selling near the highs. Reconciliation: the market's caution aligns with the fundamental read. Revenue growth is real, the order book is structural, but near-term profitability is delayed and management's Q2–Q3 breakeven claim is unproven. The -17% drawdown from ATH is fair pricing for 'show me the profitability inflection.'

Risks, ranked by holder concern

Five ranked risks—what should worry an existing investor most

Profitability inflection timing risk

HIGH

Consolidated PAT -₹73.6 Cr and worsened QoQ by 35.5% despite 61% revenue growth. Management targets EBITDA/PAT breakeven Q2–Q3, but if Hyderabad capex drag extends or Tritium costs persist, inflection slips to H2+. Stock falls further if management misses its own guidance.

Tritium turnaround execution risk

HIGH

Trials with Fortune 100 companies are mid-to-advanced, but contracts are unsigned. Conversion to USD 20–30M by CY27 is aspirational. If trials delay into H2 CY27, profitability inflection pushed back further, compounding consolidated losses.

Hyderabad transition drag extends

HIGH

Parallel run costs (₹8.7 Cr Q1) and depreciation jump (₹10.3 Cr YoY increase) are 'planned and time-bound,' but no end date given. If Gurgaum transition takes 3+ quarters vs. 2, breakeven slips. Management credibility at risk.

Supply chain & forex headwinds persist

MEDIUM

Input costs (semiconductors, plastics, copper) cited as ongoing constraint. Gross margin down 3.6% YoY. Further rupee weakness re-accelerates costs and limits operating leverage on 61% revenue growth.

Working capital intensity ties up cash

MEDIUM

57% revenue growth lifts receivables and inventory. Parallel plant transition extends cash cycle. If growth slows or collections lengthen, cash pressure ensues—especially with debt at ₹370 Cr.

The core debate

Bull vs. bear: where the stock goes next

Bull case: Exicom is a structural pick for India's energy transition (5G, EV, BESS). ₹1,400 Cr order book = 60+ months visibility. Standalone is profitable (₹4.9 Cr PAT) and growing fast (80% in Critical Power). Tritium trials are advancing. Hyderabad capex is a one-time drag; once it phases out (Q2–Q3 as guided), consolidated profitability will inflect sharply. Near-term loss is noise; the real story is medium-term (FY28+) earnings surge. Bear case: Consolidated loss of ₹73.6 Cr is not noise—it worsened QoQ by 35.5% despite +61% revenue growth. That's a red flag for deeper margin pressure or execution risk, not a temporary capex hiccup. Hyderabad costs may not phase as fast as guided ('time-bound' with no dates). Tritium has been 'mid-stage' for 2+ years; conversion risk is real. Management says Q2–Q3 breakeven, but the data doesn't back certainty. If profitability inflection slips, stock falls to new lows. The honest read: Exicom has genuine structural tailwinds and standalone strength. But consolidated profitability is the real test, and it's failed to inflect on 61% growth. The market is right to be cautious. Q2 FY27 will settle this: if Hyderabad parallel costs phase and EBITDA approaches breakeven as guided, the bull case resumes. If consolidated losses persist, management guidance was wrong and stock has room to fall.

What to watch next

Three concrete catalysts—in order of urgency

1 · Q2 FY27 consolidated EBITDA trajectory
Does Hyderabad parallel run cost (₹8.7 Cr in Q1) decline materially? Does consolidated EBITDA move toward breakeven? This is THE debate resolver. A narrowing EBITDA loss with visible cost phase-out restores credibility. A widening loss or flat trajectory means guidance was overly optimistic.
2 · Tritium Fortune 100 trial closure and order signing
When do large contracts convert from trials to signed deals? If Q4 FY27 or early CY27, the USD 20–30M revenue target looks achievable and Tritium profitability improves. If pushed to H2 CY27+, the turnaround narrative stalls and consolidated breakeven slips.
3 · Critical Power order execution and export ramp
Can exports scale from ₹15 Cr (8% of segment) to target 15% of revenue by FY27 end? Track BharatNet and BSNL Phase 2 execution pace in H2. This determines whether order book translates to near-term growth as guided.

The number to track

Consolidated EBITDA in Q2 FY27. If it narrows materially (e.g., -₹15 Cr or better) with visible Hyderabad cost phase-out, management is executing and profitability is on track. If it stays deeply negative (worse than -₹20 Cr) or widens, their Q2–Q3 breakeven claim was aspirational and the stock has room to fall further. Watch the bridge—not just the number, but the drivers.

Exicom delivered genuine revenue growth (61% YoY) and a substantive order book (₹1,400 Cr, 60+ months visibility). Standalone is profitable and growing. But near-term consolidated profitability remains delayed by planned capex (Hyderabad) and Tritium's investment phase. The market's -17% drawdown from all-time highs is fair pricing for uncertainty. Hold if you own for the medium-term (FY28+) structural story. Don't add until Q2 shows Hyderabad costs phasing and consolidated EBITDA approaching breakeven. The stock proves itself on the next earnings call.

Informational and educational content only. Not investment advice.